Somewhat Favorable News Coverage Somewhat Unlikely to Impact Oasmia Pharmaceutical AB (OASM) Share Price
News articles about Oasmia Pharmaceutical AB (NASDAQ:OASM) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oasmia Pharmaceutical AB earned a news impact score of 0.07 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.9460963205592 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Oasmia Pharmaceutical AB (NASDAQ OASM) traded down 5.35% on Thursday, hitting $1.06. The company’s stock had a trading volume of 25,805 shares. Oasmia Pharmaceutical AB has a 52 week low of $0.85 and a 52 week high of $3.70. The company’s market cap is $44.55 million. The stock’s 50 day moving average is $1.04 and its 200-day moving average is $1.75.
The firm also recently disclosed a … dividend, which was paid on Monday, July 24th. Investors of record on Monday, July 17th were paid a $0.0185 dividend. The ex-dividend date of this dividend was Thursday, July 13th.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Oasmia Pharmaceutical AB (OASM) Share Price” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/08/17/oasmia-pharmaceutical-ab-oasm-earns-media-impact-score-of-0-07-updated.html.
Oasmia Pharmaceutical AB Company Profile
Oasmia Pharmaceutical AB (publ) develops, produces, markets, and sells drugs for human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The companys approved products include Paccal Vet-CA1 for the treatment of mammary carcinoma and squamous cell carcinoma in dogs; and Paclical for the treatment of ovarian cancer.
Receive News & Stock Ratings for Oasmia Pharmaceutical AB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oasmia Pharmaceutical AB and related stocks with our FREE daily email newsletter.